ACE2 Gene Polymorphism And Its Clinical Correlation With Biochemical Imbalance
Keywords:
ACE2 polymorphism, HbA1c, liver transaminases, lipid profile, vitamin DAbstract
Angiotensin converting enzyme 2 (ACE2) plays a pivotal role in the renin–angiotensin system, with emerging evidence linking its genetic variants to metabolic and hepatic homeostasis. This cross sectional study assessed the association between a common ACE2 single nucleotide polymorphism and key biochemical markers in 200 adult patients undergoing routine health evaluations. Genotyping was performed by PCR RFLP, and fasting blood samples were analysed for glycosylated hemoglobin (HbA1c), liver transaminases (SGOT/AST and SGPT/ALT), a full lipid panel (total cholesterol, HDL, LDL, triglycerides), and serum 25 hydroxyvitamin D₃. Statistical comparisons between ACE2 positive (n = 155) and ACE2 negative (n = 45) groups employed Student’s t tests, Mann–Whitney U tests, and chi square analyses as appropriate, with significance defined as p < 0.05. Carriers of the ACE2 polymorphism demonstrated a modest but statistically significant elevation in mean HbA1c (4.56 ± 1.88 % vs. 3.83 ± 1.73 %; p = 0.017), indicating a shift toward subclinical glucose dysregulation despite low prevalence of overt diabetes. SGOT levels were significantly higher among carriers (55.7 ± 21.0 IU/L vs. 46.7 ± 15.9 IU/L; p = 0.0027), while SGPT exhibited a non significant upward trend. No differences were observed in total cholesterol, HDL, LDL, or triglyceride concentrations between genotypic groups (all p > 0.05). Serum vitamin D₃ deficiency (< 20 ng/mL) was ubiquitous (≈48 % of participants) and did not differ by ACE2 status (p = 0.42). These findings suggest that ACE2 genetic variation contributes to subtle impairments in glucose handling and low grade hepatic stress, without appreciable effects on lipid metabolism or vitamin D status. Incorporation of ACE2 genotyping into risk stratification protocols could enable early identification of individuals at risk for metabolic derangements, guiding tailored lifestyle or pharmacologic interventions. Future longitudinal and mechanistic studies are warranted to determine whether ACE2 driven metabolic shifts translate into increased incidence of type 2 diabetes or hepatic pathology, and to explore the therapeutic potential of targeting the ACE2/angiotensin (1–7) axis.
Downloads
Metrics
References
Andrukhova, O., Slavic, S., Zeitz, U., Riesen, S. C., Heidenreich, S., Lanske, B., & Erben, R. G. (2014). Vitamin D is a regulator of FGF23 production and phosphate excretion in vivo. Journal of Bone and Mineral Research, 29(3), 685–693.
Bindom, S. M., & Lazartigues, E. (2019). The sweeter side of ACE2: Physiological evidence for a role in diabetes. Molecular and Cellular Endocrinology, 302(2), 193–202.
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., … Penninger, J. M. (2022). Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature, 417(6891), 822–828.
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., … Acton, S. (2020). A novel angiotensin converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circulation Research, 87(5), E1–E9.
Forouhi, N. G., Luan, J., Cooper, A., Boucher, B. J., & Wareham, N. J. (2008). Baseline serum 25 hydroxy vitamin D is predictive of future glycemic status and insulin resistance. Diabetes, 57(10), 2619–2625.
Gupte, M., Boustany Kari, C. M., Bharadwaj, K., Police, S., Thatcher, S., Gong, M. C., … Morris, M. (2008). ACE2 is expressed in mouse adipocytes and regulated by a high fat diet. American Journal of Physiology Regulatory, Integrative and Comparative Physiology, 295(3), R781–R788.
Herath, C. B., Warner, F. J., Lubel, J. S., Dean, R. G., Jia, Z., Lew, R. A., … Angus, P. W. (2007). Upregulation of hepatic angiotensin converting enzyme 2 (ACE2) and angiotensin 1–7 levels in experimental biliary fibrosis. Journal of Hepatology, 47(3), 387–395.
Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281.
Imai, Y., Kuba, K., Rao, S., Huan, Y., Yang, P., Sarao, R., … Penninger, J. M. (2005). Angiotensin converting enzyme 2 protects from severe acute lung failure. Nature, 436(7047), 112–116.
Li, Y. C., Kong, J., Wei, M., Chen, Z. F., Liu, S. Q., & Cao, L. P. (2002). 1,25 Dihydroxyvitamin D₃ is a negative endocrine regulator of the renin–angiotensin system. Journal of Clinical Investigation, 110(2), 229–238.
Lubel, J. S., Herath, C. B., Burrell, L. M., & Angus, P. W. (2008). Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology, 23(9), 1327–1338.
Lubel, J. S., Herath, C. B., Tchongue, J., Grace, J., Jia, Z., Spencer, K., … Angus, P. W. (2021). Angiotensin (1–7), an alternative metabolite of the renin–angiotensin system, is upregulated in human liver disease and has antifibrotic activity in the bile duct–ligated rat. Clinical Science, 117(11), 375–386.
Patel, S. K., Wai, B., Ord, M., MacIsaac, R. J., Grant, S., Velkoska, E., & Burrell, L. M. (2012). Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. American Journal of Hypertension, 25(2), 216–222.
Shiuchi, T., Iwai, M., Li, H. S., Wu, L., Min, L. J., Li, J. M., ... & Horiuchi, M. (2024). Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension, 43(5), 1003–1010.
Tikellis, C., & Thomas, M. C. (2012). Angiotensin converting enzyme 2 (ACE2) is a key modulator of the renin–angiotensin system in health and disease. International Journal of Peptides, 2012, 256294.
Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q., ... & Scholey, J. W. (2007). Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. American Journal of Pathology, 171(2), 438–451.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
